

# Neha J. Pagidipati, MD, MPH, MHS

## CURRICULUM VITAE

Date: January 6, 2021

---

Name: Neha J. Pagidipati, MD, MPH, FACC

Primary Academic Appointment: Duke University, Durham, North Carolina

Primary Academic Department: Department of Medicine, Division of Cardiology

Secondary Appointment: Duke Clinical Research Institute

Present Academic Rank and Title: Assistant Professor of Medicine

Date and Rank of First Duke Faculty Appointment: Assistant Professor of Medicine 07/01/2017

Medical Licensure: Medical Board Physician 09/15/2013  
NC License #2013-00384

Specialty Certifications and Dates: American Board of Internal Medicine 08/24/2011  
License #318961

American Board of Cardiovascular Medicine 09/27/2016  
License #318961

Fellow of the American College of Cardiology 11/03/2020

Date of Birth: 09/15/1981

Place: Jacksonville, Florida, USA

Citizen of: United States of America

<u>Education</u>	<u>Institution</u>	<u>Date</u>	<u>Degree</u>
High School	Bolles School Jacksonville, FL	1999	Diploma
College	Harvard University Cambridge, MA	2003	B.A.
Medical School	Harvard Medical School Boston, MA	2008	M.D.
	Harvard School of Public Health Boston, MA	2013	M.P.H.

### Professional Memberships:

American College of Cardiology	2013 – Present
American Heart Association	2016 – Present
National Lipid Association	2017 – Present
American Diabetes Association	2018 – Present

### Professional Training and Academic Career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Brigham and Women's Hospital	Internal Medicine Residency	2008 - 2011
Brigham and Women's Hospital	Nocturnist	2011 – 2013
Brigham and Women's Hospital	Global Women's Health Fellowship	2011 – 2013
Duke University	Cardiology Fellowship	2013 - 2017
Duke Clinical Research Institute	Chief Fellow	2016 - 2017

### Refereed Publications:

1. **Pagidipati N**, Obstein K, Rucker-Schmidt R, Odze R, Thompson C. Acute hepatitis due to epstein-barr virus in an immunocompetent patient. *Dig Dis Sci*. 2010 Apr;55(4):1182-5. PMID: 19459045.
2. Gaziano TA, **Pagidipati N**. Scaling up chronic disease prevention interventions in lower- and middle-income countries. *Annu Rev Public Health*. 2013;34:317-35. PMID: 23297660; PMCID: PMC3686269.
3. **Pagidipati NJ**, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. *Circulation*. 2013 Feb 12;127(6):749-56. PMID: 23401116; PMCID: PMC3712514.
4. **Pagidipati NJ**, Huffman MD, Jeemon P, Gupta R, Negi P, Jaison TM, Sharma S, Sinha N, Mohanan P, Muralidhara BG, Bijulal S, Sivasankaran S, Puri VK, Jose J, Reddy KS, Prabhakaran D. Association between gender, process of care measures, and outcomes in ACS in India: results from the detection and management of coronary heart disease (DEMAT) registry. *PLoS One*. 2013 Apr 24;8(4):e62061. PMID: 23637963; PMCID: PMC3634747.
5. Hemal K, **Pagidipati NJ**, Coles A, Dolor RJ, Mark DB, Pellikka PA, Hoffmann U, Litwin SE, Daubert MA, Shah SH, Ariani K, Bullock-Palmer RP, Martinez B, Lee KL, Douglas PS. Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. *JACC Cardiovasc Imaging*. 2016 Apr;9(4):337-46. PMID: 27017234; PMCID: PMC4982809.  
✓ This paper was highlighted in a review entitled Sex Differences in CAD Diagnosis in *Nature Reviews Cardiology* | Published online 7 Apr 2016.

6. **Pagidipati NJ**, Pencina M, Sniderman AD. The Enigma of Glucose and Lipid Metabolism. *JAMA Cardiol.* 2016 May 1;1(2):145-6. PMID: 27437884.
7. **Pagidipati NJ**, Hemal K, Coles A, Mark DB, Dolor RJ, Pellikka PA, Hoffmann U, Litwin SE, Udelson J, Daubert MA, Shah SH, Martinez B, Lee KL, Douglas PS. Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease. *J Am Coll Cardiol.* 2016 Jun 7;67(22):2607-16. PMID: 27058908; PMCID: PMC4892993.
8. **Pagidipati NJ**, Peterson ED. Acute coronary syndromes in women and men. *Nat Rev Cardiol.* 2016 Aug;13(8):471-80. PMID: 27256211.
9. **Pagidipati NJ**, Douglas PS. The Puzzle of Noninvasive Testing in Women: Filling in the Pieces With the CRESCENT Trial (Calcium Imaging and Selective CT Angiography in Comparison to Functional Testing for Suspected Coronary Artery Disease). *Circ Cardiovasc Imaging.* 2017 Feb;10(2). PMID: 28174198.
10. **Pagidipati NJ**, Granger CB. Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age. *Ann Intern Med.* 2017 Mar 21;166(6):JC26. PMID: 28320000.
11. **Pagidipati NJ**, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. *JAMA.* 2017 Apr 18;317(15):1563-1567. PMID: 28418481; PMCID: PMC5470349.
12. Mentz RJ, Bethel MA, Gustavson S, Thompson VP, **Pagidipati NJ**, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). *Am Heart J.* 2017 May;187:1-9. PMID: 28454792.
13. **Pagidipati NJ**, Hess CN, Clare RM, Akerblom A, Tricoci P, Wojdyla D, Keenan RT, James S, Held C, Mahaffey KW, Klein AB, Wallentin L, Roe MT. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. *Am Heart J.* 2017 May;187:53-61. PMID: 28454808.
14. **Pagidipati NJ**, Hellkamp A, Thomas L, Gulati M, Peterson ED, Wang TY. Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. *JAMA Cardiol.* 2017 Sep 1;2(9):1040-1042. PMID: 28724116.
15. **Pagidipati NJ**, Navar AM, Pencina MJ. Guideline Recommendations for Statin Therapy-Reply. *JAMA.* 2017 Sep 12;318(10):964. PMID: 28898376.
16. **Pagidipati NJ**, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). *Circulation.* 2017 Sep 26;136(13):1193-1203. PMID: 28626088; PubMed Central PMCID: PMC5614823.
17. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, **Pagidipati NJ**, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2017 Sep 28;377(13):1228-1239. PMID: 28910237.
18. Sharma A, Sekaran NK, Coles A, **Pagidipati NJ**, Hoffmann U, Mark DB, Lee KL, Al-Khalidi HR, Lu MT, Pellikka PA, Trong QA, Douglas PS. Impact of Diabetes Mellitus on the Evaluation of

Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial. *J Am Heart Assoc.* 2017 Oct 31;6(11). PMID: 29089344.

19. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, **Pagidipati NJ**, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol.* 2018 Feb;6(2):105-113. PMID: 29221659.
20. Kochar A, Chen AY, Sharma PP, **Pagidipati NJ**, Fonarow GC, Cowper PA, Roe MT, Peterson ED, Wang TY. Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. *J Am Heart Assoc.* 2018 Jun 30;7(13). PMID: 29960995.
21. Prabhakaran D, Singh K, Roth GA, Banerjee A, **Pagidipati NJ**, Huffman MD. Cardiovascular Diseases in India Compared With the United States. *J Am Coll Cardiol.* 2018 Jul 3;72(1):79-95. PMID: 29957235.
22. **Pagidipati NJ**, Clare RM, Keenan RT, Chiswell K, Roe MT, Hess CN. Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease. *J Am Heart Assoc.* 2018 Aug 21;7(16):e009328. PMID: 30369327.
23. Bhavsar NA, Gao A, Phelan M, **Pagidipati NJ**, Goldstein BA. Value of Neighborhood Socioeconomic Status in Predicting Risk of Outcomes in Studies That Use Electronic Health Record Data. *JAMA Netw Open.* 2018 Sep 7;1(5):e182716. PMID: 30646172
24. **Pagidipati NJ**, Hellkamp AS, Sharma PP, Wang TY, Fonarow GC, Pencina M. High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. *Am Heart J.* 2018 Oct;204:151-155. PMID: 30121016
25. Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, **Pagidipati NJ**, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. *J Am Heart Assoc.* 2018 Oct 2;7(19):e009304. PMID: 30371301
26. Robinson JG, Williams KJ, Gidding S, Borén J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybjaerg-Hansen A, Douglas PS, Nicholls SJ, **Pagidipati N**, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. *J Am Heart Assoc.* 2018 Oct 16;7(20):e009778. PMID: 30371276.
27. **Pagidipati NJ**, Coles A, Hemal K, Lee KL, Dolor RJ, Pellikka PA, Mark DB, Patel MR, Litwin SE, Daubert MA, Shah SH, Hoffmann U, Douglas PS; PROMISE Investigators. Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. *Am Heart J.* 2018 Nov 9;208:28-36. PMID: 30529930
28. **Pagidipati NJ**, Mudrick DW, Chiswell K, Brucker A, Peterson ED, Douglas PS. Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease. *Am Heart J.* 2018 Dec;206:51-60. PMID: 30317061
29. Christopher BA, **Pagidipati NJ**. Clinical Updates in Women's Health Care Summary: Evaluation and Management of Lipid Disorders: Primary and Preventive Care Review. *Obstet Gynecol.* 2019 Mar;133(3):609. PMID: 30801472
30. Sharma A, Coles A, Sekaran NK, **Pagidipati NJ**, Lu MT, Mark DB, Lee KL, Al-Khalidi HR, Hoffmann U, Douglas PS. Stress Testing Versus CT Angiography in Patients With Diabetes and

Suspected Coronary Artery Disease. *J Am Coll Cardiol*. 2019 Mar 5;73(8):893-902. PMID: 30819356

31. Setji TL, Page C, **Pagidipati N**, Goldstein BA. DIFFERENCES IN ACHIEVING HBA1C GOALS AMONG PATIENTS SEEN BY ENDOCRINOLOGISTS AND PRIMARY CARE PROVIDERS. *Endocr Pract*. 2019 May;25(5):461-469. PMID: 30720349
32. Goldstein BA, Phelan M, **Pagidipati NJ**, Holman RR, Pencina MJ, Stuart EA. An outcome model approach to transporting a randomized controlled trial results to a target population. *J Am Med Inform Assoc*. 2019 May 1;26(5):429-437. PMID: 30869798
33. Granger CB, Nelson AJ, **Pagidipati NJ**. Risk of Total Events With Icosapent Ethyl: Can We Reduce it? *J Am Coll Cardiol*. 2019 Jun 11;73(22). PMID: 31171085
34. Litwin SE, Coles A, **Pagidipati N**, Lee KL, Pellikka PA, Mark DB, Udelson JE, Hoffmann U, Douglas PS; PROMISE Investigators. Effects of obesity on noninvasive test results in patients with suspected cardiac ischemia: Insights from the PROMISE trial. *J Cardiovasc Comput Tomogr*. 2019 Jul-Aug;13(4):211-218. PMID: 30954400
35. Nelson AJ, Peterson ED, **Pagidipati NJ**. Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. *Prog Cardiovasc Dis*. 2019 Jul-Aug;62(4):306-314. PMID: 31301314
36. **Pagidipati NJ**, Lopes RD. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know? *J Thorac Cardiovasc Surg*. 2019 Oct;158(4):1113-1117. PMID: 31301898
37. Gao Y, Peterson E, **Pagidipati N**. Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease. *Clin Cardiol*. 2019 Nov;42(11):1063-1070. PMID: 31448852
38. Fudim M, White J, **Pagidipati NJ**, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. *Circulation*. 2019 Nov 12;140(20):1613-1622. PMID: 31542942
39. Goldstein BA, Phelan M, Pagidipati **NJ**, Peskoe SB. How and when informative visit processes can bias inference when using electronic health records data for clinical research. *J Am Med Inform Assoc*. 2019 Dec 1;26(12):1609-1617. PMID: 31553474
40. Bhatt AS, Luo N, Solomon N, **Pagidipati NJ**, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ; TECOS Study Group. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. *Am Heart J*. 2019 Dec;218:57-65. PMID: 31707329
41. Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, **Pagidipati NJ**, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. *Circ Cardiovasc Interv*. 2019 Dec;12(12). PMID: 31752517
42. **Pagidipati NJ**, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED; TECOS Study Group. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. *Am Heart J*. 2020 Jan;219:47-57. PMID: 31707324
43. Litwin SE, Coles A, Hill CL, Alhanti B, **Pagidipati N**, Lee KL, Pellikka PA, Mark DB, Udelson JE, Cooper L, Tardif JC, Hoffmann U, Douglas PS; PROMISE investigators. Discordances between

predicted and actual risk in obese patients with suspected cardiac ischaemia. *Heart*. 2020 Feb;106(4):273-279. PMID: 31601728

44. Farmer HR, Wray LA, Xian Y, Xu H, **Pagidipati N**, Peterson ED, Dupre ME. Racial Differences in Elevated C-Reactive Protein Among US Older Adults. *J Am Geriatr Soc*. 2020 Feb;68(2):362-369. PMID: 31633808
45. Reed SD, Li Y, Dakin HA, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, **Pagidipati NJ**, Bethel MA, Gray AM, Holman RR, Hernandez AF; EXSCEL Study Group. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). *Diabetes Care*. 2020 Feb;43(2):374-381. PMID: 31806653
46. Sharma A, **Pagidipati NJ**, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. *Circulation*. 2020 Mar 10;141(10):843-862. PMID: 31992065
47. Truby LK, O'Connor C, Fiuzat M, Stebbins A, Coles A, Patel CB, Granger B, **Pagidipati N**, Agarwal R, Rymer J, Lowenstern A, Douglas PS, Tulskey J, Rogers JG, Mentz RJ. Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial. *Circ Heart Fail*. 2020 Apr;13(4). PMID: 32268795
48. Goyal A, **Pagidipati N**, Hill CL, Alhanti B, Udelson JE, Picard MH, Pellikka PA, Hoffmann U, Mark DB, Douglas PS. Clinical and Economic Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. *Circ Cardiovasc Imaging*. 2020 Apr;13(4). PMID: 32268807
49. Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The association between triglycerides and incident cardiovascular disease: What is "optimal"? 2020 May 6:S1933-2874(20)30079-9. PMID: 32571728
50. Gao Y, Peterson E, **Pagidipati N**. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. *Am Heart J*. 2020 Jun;224:47-53. PMID: 32304879
51. Lumsden RH, **Pagidipati NJ**, Phelan MP, Chiswell K, Peterson ED. Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System. *Am J Prev Med*. 2020 Jun;58(6):817-824. PMID: 32444000
52. Armstrong SC, Windom M, Bihlmeyer NA, Li JS, Shah SH, Story M, Zucker N, Kraus WE, Pagidipati N, Peterson E, Wong C, Wiedemeier M, Sibley L, Berchuck SI, Merrill P, Zizzi A, Sarria C, Dressman HK, Rawls JF, Skinner AC. Rationale and design of "Hearts & Parks": study protocol for a pragmatic randomized clinical trial of an integrated clinic-community intervention to treat pediatric obesity. 2020 June 26;20(1):308. PMID: 32590958
53. Nelson AJ, Navar AM, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, **Pagidipati NJ**. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial). *Am J Cardiol*. 2020 Jul 12. PMID: 32773223
54. Carnicelli AP, Clare R, Chiswell K, Lytle B, Bjursell M, Perl S, Andersson K, Hedman K, **Pagidipati N**, Vemulapalli S, Roe MT, Mentz RJ. Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. *Am J Cardiol*. 2020 Jul 15;127:64-72. PMID: 32386813

55. Ellison S, Abdulrahim JW, Kwee LC, Bihlmeyer NA, **Pagidipati N**, McGarrah R, Bain JR, Kraus WE, Shah SH. Novel plasma biomarkers improve discrimination of metabolic health independent of weight. *Sci Rep*. 2020 Dec 7;10(1):21365. PMID: 33288813
56. Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, **Pagidipati NP**, Shah SH, Roe MT, Patel MR, Jones WS. Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease. *J Am Heart Assoc*. 2020 Dec 15;9(24). PMID: 33287625
57. Wosik J, Clowse MEB, Overton R, Adagarla B, Economou-Zavlanos N, Cavalier J, Henao R, Piccini JP, Thomas L, Pencina MJ, **Pagidipati NJ**. Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. *Am Heart J*. 2021 Jan;231:1-5. PMID: 33137309
58. Nelson AJ, Ardissino M, Haynes K, Shambhu S, Eapen ZJ, McGuire DK, Carnicelli A, Lopes RD, Green JB, O'Brien EC, **Pagidipati NJ**, Granger CB. Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. *J Am Heart Assoc*. 2021 Jan 19;10(2). PMID: 33432843

### Non-Refereed Publications:

1. Blumer V, **Pagidipati NJ**. Hypertensive Disorders of Pregnancy and Long-Term Heart Failure Risk: A Missed Opportunity for Prevention. *Hypertension*. 2020 Nov;76(5):1420-1422. PMID: 33026911

### Posters, Abstracts and Oral Presentations:

#### A. Posters:

1. **Pagidipati NJ**, Mudrick DW, Chiswell K, Brucker A, Peterson ED, Douglas PS. Sex Differences in Long-term Outcomes of Patients with Non-obstructive Coronary Artery Disease. American College of Cardiology 2016. Chicago, IL. \*Moderated Poster Presentation.
2. **Pagidipati NJ**, Hess CN, Clare RM, Akerblom A, Tricoci P, Wojdyla D, Keenan RT, James S, Held C, Mahaffey KW, Klein AB, Wallentin L, Roe MT. Does a clinical history of gout influence the relationship of serum uric acid levels and cardiovascular outcomes among patients with acute coronary syndromes? European Society of Cardiology 2016. Rome, Italy. \*Best Poster Presentation.
3. **Pagidipati NJ**, Hellkamp A, Thomas L, Gulati M, Peterson ED, Wang T. Use of Prescription Smoking Cessation Medications after Myocardial Infarction in Community Practice. American Heart Association 2016. New Orleans, LA.
4. **Pagidipati NJ**, Coles A, Hemal K, Lee KL, Dolor RJ, Pellikka PA, Mark DB, Patel MR, Litwin SE, Daubert, MA, Shah SH, Hoffmann U, Douglas PS. Sex Differences in Management and Outcomes of Patients with Stable Symptoms Suggestive of Coronary Artery Disease: Insights from the PROMISE Trial. American Heart Association 2016. New Orleans, LA.
5. Litwin SE, Coles A, **Pagidipati NJ**, Lee KL, Pellikka PA, Mark DB, Udelson JE, Hoffmann U, Douglas PS. Effects of Obesity on Noninvasive Testing and Angiography Results in Patients With Suspected Cardiac Ischemia: Insights from the PROMISE Trial. American Heart Association 2016. New Orleans, LA.
6. Alexander K, Pellikka P, Litwin SE, Coles A, **Pagidipati NJ**, Lee KL, Mark DB, Udelson JE, Hoffmann U, Douglas PS. Impact of age on noninvasive testing strategy in patients

- with symptoms concerning for coronary artery disease: Insights from the PROMISE trial. American Heart Association 2016. New Orleans, LA.
7. **Pagidipati NJ**. Sex Differences in Functional Stress Test vs CT Angiography Results and Prognosis in Symptomatic Patients with Suspected Coronary Artery Disease: Insights from the PROMISE Trial. ACCEL: November: 2016:disc 1; interview 6.
  8. **Pagidipati NJ**, Sharma P, Hellkamp A, Wang T, Fonarow GC, Pencina M. Examination of hsCRP elevation in patients with history of myocardial infarction in the US. American College of Cardiology 2017. Washington, DC.
  9. **Pagidipati NJ**, Navar AM, Pieper KS, Green JB, Bethel A, Armstrong PW, Josse RG, McGuire DK, Likhnygina Y, Cornel JH, Halvorsen S, Strandberg T, Delibasi T, Holman RR, Peterson ED, on behalf of TECOS Study Group. Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial. American Heart Association Quality of Care and Outcomes Research 2017.
  10. Bhatt AS, Lou N, Solomon N, **Pagidipati NJ**, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White H, Holman RR, Peterson ED, Mentz RJ. International Variation in Management and Clinical Outcome of Patients with Type 2 Diabetes and Heart Failure: Insights from TECOS. American Heart Association 2017. Anaheim, CA.
  11. **Pagidipati NJ**, Phelan M, Chiswell K, Peterson ED. Prevalence and Management of Adult Obesity in a Large Academic Health System. American Heart Association 2017. Anaheim, CA.
  12. Reed SD, Li Y, Dakin H, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, **Pagidipati N**, Bethel MA. EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. American Diabetes Association 2018. Chicago, IL.
  13. Reed SD, Li Y, Dakin H, Becker F, Leal J, Gustavson SM, Kartman B, Wittbrodt E, Mentz RJ, **Pagidipati N**, Bethel MA, Gray AM, Holman RR, Hernandez AF. Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL. 54th Annual Meeting of the European Association for the Study of Diabetes (EASD). October 1-5, 2018, Berlin, Germany.
  14. Badjatiya A, Merrill P, Buse J, Goodman SG, Katona B, Iqbal N, Ohman P, **Pagidipati N**, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Patients With Diabetes and peripheral Arterial Disease: Results From the EXSCEL Trial. American College of Cardiology Scientific Sessions, March 2019, New Orleans, LA.
  15. Navar AM, **Pagidipati N**, Mulder H, Aberra T, Philip S, Granowitz C, Peterson E. Triglycerides as a Risk Factor for Coronary Heart Disease: What measure and what cutoff? Poster presented at the American College of Cardiology Scientific Sessions, March 2019, New Orleans, LA.
  16. **Pagidipati NJ**, Navar AM, Mulder H, Wodjyla D, Phillips S, Granowitz C, Peterson ED. Association between Triglycerides and Residual Cardiovascular (CVD) Risk in Patients with Type 2 Diabetes and Established CVD: An Analysis of the BARI2D Trial. American Diabetes Association 79<sup>th</sup> Scientific Sessions, San Francisco, CA.
  17. **Pagidipati N**, Wodjyla DM, Robinson J, Navar AM, Peterson ED, Pencina M. Risk prediction for ASCVD in primary prevention patients on statin therapy. European Society of Cardiology Scientific Sessions 2019, Paris, France.



18. Kammerlander AA, Mayrhofer T, Ferencik M, **Pagidipati NJ**, Karady J, Ginsburg GS, Lu MT, Bittner DO, Puchner SB, Bihlmeyer NA, Meyersohn NM, Emami H, Shah SH, Douglas PS, Hoffman U. Metabolic health, and not obesity, is the main driver of outcomes in patients with stable chest pain. Poster presented at the American College of Cardiology Scientific Sessions, March 2020, Chicago, IL

## **B. Oral Presentations:**

1. Sex Differences in Functional Stress Test vs CT Angiography Results and Prognosis in Symptomatic Patients with Suspected Coronary Artery Disease Insights from the PROMISE Trial. **Pagidipati NJ**, Hemal K, Coles A, Mark DB, Dolor RJ, Pellikka PA, Hoffmann U, Litwin SE, Udelson J, Daubert, MA, Shah SH, Martinez, B, Lee KL, Douglas PS. American College of Cardiology Scientific Sessions 2016, Chicago, IL. \*Featured Clinical Research
2. The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial. **Pagidipati NJ**, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED. European Society of Cardiology Congress 2017, Barcelona, Spain.
3. "Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial". Mentz RJ, Bethel MA, Thompson VP, Likhnygina Y, Buse JB, Chan JC, Cjoi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, **Pagidipati NJ**, Poulter N, Ramachandran A, Zinman B, Holman RR, Hernandez AF, on behalf of EXSCEL Study Group. American Heart Association Scientific Sessions 2017, Washington, DC. \*Late-Breaking Science Session
4. "Association between High-Density Lipoprotein Cholesterol and Cardiovascular Events and All-Cause Mortality in a Primary Prevention Population". **Pagidipati NP**, Phelan M, Navar AM, Pencina MJ, Peterson ED. American Heart Association Scientific Sessions 2017, Washington, DC.
5. "Implications of Inconclusive Noninvasive Test Results in Stable Patients with Suspected Coronary Artery Disease: Insights from the PROMISE Trial". **Pagidipati NJ**, Hill L, Coles A, Udelson JE, Picard MH, Pellikka PA, Lee KL, Hoffmann U, Douglas PS. American Heart Association Scientific Sessions 2017, Washington, DC.

## **C. Moderated Conference Sessions:**

1. Co-management of Patients with Diabetes and Heart Disease Session. American Heart Association Scientific Sessions 2018, November 10, 2018, Chicago, IL
2. Abstract Oral Session entitled New Insights from Clinical Trials in Diabetes. American Heart Association Scientific Sessions 2018, November 11, 2018, Chicago, IL
3. Featured Population Science Session. American Heart Association Scientific Sessions 2019, November 16, 2019, Philadelphia, PA
4. Examining Effects of Novel Therapeutic Agents in Diabetes. American Heart Association Scientific Sessions 2019, November 16, 2019, Philadelphia, PA

## **Chapters in Books:**

1. Gaziano T, **Pagidipati N**. Chapter 6: Global Cardiovascular Therapy. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 4<sup>th</sup> Ed. Antman EA and Sabatine M, Editors. Elsevier Saunders, Philadelphia. 2013. p. 75-82.

**Other:**

**A. Invited Lectures:**

1. Triangle Women in STEM. "How to prevent cardiovascular disease: weight loss, cholesterol lowering, and beyond". Duke University, Durham, NC, February 21, 2018.
2. Duke Alumni Women's Weekend. "Heart, Mind and Body: Women's Health and Wellness". Duke University, Durham, NC, February 23, 2018.
3. DCRI Research Forum Series "Cardiovascular Outcomes for Diabetes Drugs: Lessons Learned and Path Forward" Panel Discussion. Duke Clinical Research Institute, Durham, NC, March 6, 2018.
4. "Competing Risks of Heart Failure and Cardiovascular Events in Diabetes". American Heart Association Scientific Sessions 2018, Main Event, Chicago, IL, November 11, 2018.
5. Cardiovascular Disease Risk Reduction in Type 2 Diabetes: Turning what we know into what we do. Endocrine Grand Rounds, Duke University, Durham, NC. July 26, 2019.
6. Personalizing Obesity Care Within Duke. Medicine Grounds Rounds, Duke University, Durham, NC. September 6, 2019.
7. How to Prevent Multi-organ Dysfunction in Diabetes. American Heart Association Scientific Sessions 2019, Philadelphia, PA, November 16, 2019.
8. Reducing Cardiovascular Risk in Patients with Diabetes. Grand Rounds, Bayfront Health, St. Petersburg, FL, January 9, 2020.
9. Heart to Heart for Go Red for Women. American Heart Association, National Wear Red Day, Breakfast in Red Event, Raleigh, NC, February 7, 2020.
10. How to prevent cardiovascular disease: weight loss, cholesterol lowering, and beyond. Duke Diet and Fitness Center, Durham, NC, February 27, 2020.
11. Reducing Cardiovascular Risk in Patients with Diabetes. Duke Cardiology APPs, Duke University, Durham, NC, April 8, 2020.
12. Exploring the gap between data and clinical practice. European Society of Cardiology 2020 Scientific Sessions.
13. Anti-hyperglycemic Agents with Cardiovascular Benefit. ACC.20 Cardiometabolic Series Symposia – China, Virtual, September 18, 2020.
14. Transitioning from Fellowship. Duke Cardiology Fellows, Duke University, Durham, NC, September 22, 2020.
15. It's never too early to start thinking about a job. DCRI Fellows, Duke Clinical Research Institute, Durham, NC, September 23, 2020.
16. Diabetes doesn't require further CV risk stratification – really? Virtual American Heart Association 2020 Scientific Sessions.
17. Cardiovascular Disease & Diabetes Mellitus – Comorbidity Characteristic and Management Difficulties. American College of Cardiology Cardiovascular Webinar, September 25, 2020.
18. Transitioning from Fellowship. Duke 3<sup>rd</sup> Year Cardiology Fellows, Duke University, Durham, NC, September 29, 2020.

19. Possibilities in Prevention. Cardiology Grand Rounds, Duke University, Durham, NC, October 6, 2020.
20. Transitioning from Fellowship. Duke 2<sup>nd</sup> Year Cardiology Fellows, Duke University, Durham, NC, October 6, 2020.
21. Transitioning from Fellowship. Duke 1<sup>st</sup> Year Cardiology Fellows, Duke University, Durham, NC, October 13, 2020.
22. Update on guidelines on CV risk reduction in Diabetes: A cross-society perspective. Virtual American Heart Association 2020 Scientific Sessions.
23. Practical tips for cardiologists prescribing SGLT2i and GLP1RA. University of Miami Virtual Grand Rounds, October 14, 2020.
24. Implementation Science for the non-Implementation Scientist. BASS Lecture Series, Duke University, Durham, NC, November 3, 2020.
25. Advances in Diabetes and Obesity. Virtual Conference on Metabolism and Neurology, Brazilian Clinical Research Institute, November 7, 2020.
26. Know Diabetes by Heart. Professional Education Postcast Series, American Heart Association and American Diabetes Association Joint Event, December 8, 2020.
27. Content advisor: Care and Management Treatment of Patients with Cholesterol, an open dialogue. Amgen and the American Heart Association Science to Science virtual meeting, December 11, 2020.
28. A Practical Trans-Disciplinary Approach to Weight Management Within the Duke Health System. Cardiology Grand Rounds, Duke University, Durham, NC, January 19, 2021.
29. Lean on Me. SE Woman's Leadership Event, American Heart Association. Keynote speaker, Women's Health Virtual Seminar for employees and clients, Red Hat Company, January 21, 2021.
30. Women's Heart Health. 2021 Triangle Breakfast in Red Virtual Event, American Heart Association Panel Discussion, February 5, 2021.
31. Turning the 18<sup>th</sup> WCIRDC on Demand-to live. Live Zoom Panelist. 18<sup>th</sup> Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease CME Webinar, February 9, 2021.
32. Health System Approaches to Cardiometabolic Disease Prevention. Preventive Cardiology Lecture Series Conference, Virtual Event, UT Southwestern Medical Center, February 11, 2021.

**B. Invited Peer Review:**

American Heart Association Journals  
 American Heart Journal  
 American Journal of Cardiology  
 American Journal of Preventive Medicine

BMJ  
BMJ Open  
Circulation: Cardiovascular Imaging  
Circulation: Cardiovascular Quality and Outcomes  
Circulation: Imaging  
Clinical Cardiology  
Hypertension  
JAMA: Cardiology  
JAMA: Internal Medicine  
Journal of the American College of Cardiology (JACC)  
Journal of the American Medical Association (JAMA)  
Journal of Women's Health  
Obesity

**C. Professional Awards and Recognitions:**

Duke University:

2015                      Nominee for Duke House Staff Teaching Award

Duke Clinical Research Institute:

2017                      Robert M. Harrington Excellence in Fellowship Award

Duke University:

2017                      Finalist at Northwestern Cardiovascular Young Investigator Forum

Duke University:

2020                      Duke Cardiology Fellowship Mentorship Award

**D. Leadership Positions:**

2016 – 2017              Chief Fellow, Duke Clinical Research Institute  
2018 – Current           Associate Program Director, Duke Clinical Research Institute Research Fellowship Program  
2018 – Current           Associate Program Director, Duke Cardiovascular Disease Fellowship Program  
Current                      Duke Graduate Medical Education Residency Program  
Current                      Director, Duke Cardiometabolic Prevention Program

## E. Organizations and Participation:

### Abstracts Review:

2018	Abstract adjudicator for Obesity section, American Heart Association 2018 Scientific Sessions, November 2018, Chicago, IL.
2019	Abstract adjudicator for Obesity section, American Heart Association 2019 Scientific Sessions, November 2019, Philadelphia, PA.
2020	American College of Cardiology 2021 Scientific Sessions, <i>Prevention and Health Promotion: Special Populations Reviewer Group 1</i> category.  Abstract adjudicator for Obesity section, American Heart Association 2020 Scientific Sessions Virtual Conference

### Clinical Events Adjudication:

2013 – 2014	Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL), NCT01144338
2018 – 2019	A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA).
2018 – 2019	A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of the oral sGC stimulator vericiguat to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)
2018 – Present	ASCEND <ul style="list-style-type: none"><li>• Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in Non-Dialysis (ASCEND-ND)</li><li>• Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis (ASCEND-D)</li><li>• Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in Incident Dialysis (ASCEND-ID)</li><li>• Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in Non-Dialysis participants evaluating Hemoglobin and Quality of life (ASCEND-NHQ)</li><li>• Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Three times weekly dosing in Dialysis (ASCEND-TD)</li></ul>

### Committees:

#### *Educational/Academic*

2013 Member, Cardiology Fellowship Improvement Committee, Duke University  
2016 Member, Planning Committee, Duke Department of Medicine Fellows Research Retreat  
2017 Member, Steering Committee, Duke Clinical Research Institute Grand Rounds Conference  
2017 Chair, Cardiology Fellowship Advisory Committee on Fellowship Transition, Duke University  
2020 Member, DCRI 25<sup>th</sup> Anniversary Advisory Board, Duke Clinical Research Institute

#### *Clinical Study-Specific*

2019 – Present Chair, PROMISE Trial Publications Committee  
2020 Member, Baseline Health Publications Committee  
2020 Co-chair, Baseline Health Return of Results Committee

#### *Community*

2017 Member, Steering Committee for Interdisciplinary Colloquium, Clinical Nutrition, Research at Duke (“What Should I Eat, Doc?”)  
2018 Member, Community Steering Committee, Life is Why, American Heart Association and Duke Heart  
2020 Member, North Carolina CODI Collaborative Work Group, Childhood Obesity Data Initiative (CODI) 2.0 Pilot Implementation, Centers for Disease Control and Prevention (CDC) and The MITRE Corporation

#### Editor:

2017 – Present Associate Editor, American Heart Journal

#### Expert Analyses:

March 2021 Analysis on the *Circulation* article: Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial. *Circulation*. 2021;143:337–349. American College of Cardiology, Diabetes and Cardiometabolic Disease Clinical Topic Collection.

#### Mentoring of Residents, Fellows, and Faculty:

- Yumin Gao  
Post-undergraduate research mentee. Purdue University  
Research Intern, 2017-2018
- Rebecca Lumsden  
3Y Residency. Duke University School of Medicine, Internal Medicine Program  
Research Mentee, 2017-2018

- Akash Goyal, MD  
2Y Residency. Duke University School of Medicine, Internal Medicine Program  
Research Mentee, 2018-2019
- Adam Nelson, MD, PhD  
Research Fellow, Duke Clinical Research Institute  
Research Mentee, 2018-2019
- Michelle Kelsey, MD  
3Y Residency. Duke University School of Medicine, Cardiovascular Program  
Mentee, 2020-2021
- Isaac Smith, MD  
2Y Residency. Rheumatology Program  
Mentee, 2020-2021

**F. Areas of Research Interest (Basic and Applied):**

- Cardio-metabolic Disease Prevention
- Lipid Management
- Implementation of primary and secondary prevention therapies
- Lifestyle modification
- New antidiabetic therapies with cardiovascular benefit

**G. Advisory Groups:**

2019 – 2020                      AHA PCPI Foundation Preventive Care and Screening Technical Expert Panel

**H. External support - gifts, grants, and contracts:**

2015 – 2016                      Duke-Shiv Nadar University Urbanization Grant  
 2015 – 2017                      NIH T32 Grant Awardee  
 2016                                  Executive Director’s Fund Fellow Research Awardee  
 2017                                  DCRI Investing in Innovation Award  
 2018                                  Department of Medicine’s Health Data Science Award

**External Support – Gifts, Grants and Contracts:**

**PRESENT:**

<b>PI</b>	<b>% Effort</b>	<b>Approximate Amount</b>	<b>Duration</b>
DCRI 6468 (Newby/Shah) Baseline Study, LLC The Baseline Study_Kannapolis The goal of this long-term study is to develop a well-defined reference, or "baseline," of good health as well as a rich data platform that may be used to better understand the transition from health to cardiovascular disease and identify additional risk factors for cardiovascular disease. Role: Co-investigator	5%-10%	\$25,898,685	06/01/16-05/31/22
5R01-EB025020-02 (Pencina) NSF QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data The goal of this study is to build deep Poisson learning algorithms for time-to-event data and continuous outcomes collected longitudinally.	2%-5%	\$163,119	08/01/17-06/30/20
DCRI 7400 BING-58 (Granger) Boehringer Ingelheim Corporation COORDINATE Diabetes Study A study to analyze how different interventions affect guideline-recommended therapies among caregivers and patients. Participating clinics will be randomized to a basic education arm (in which patients will be treated by clinicians who receive only basic information about guideline-based therapy) or an intensive intervention arm (that focuses on coordinating care between cardiologists and endocrinologists to develop and implement an integrated, multidisciplinary care pathway).	2%-11.1%	\$8,412,514	01/01/19-03/31/21
NOVN-05 (Pagidipati) Novo Nordisk, Inc. LEADER Trial: Association between weight change and cardiometabolic risk factors in real-world population of U.S. Adults This prospective study will leverage the PCORnet network to examine the current landscape of obesity and how weight change (loss or gain) over the course of two years affects cardiometabolic risk factors.	2%-9.4%	\$386,421	01/05/19-01/04/22
5K12-HL138030-03 (Bosworth) NIH Dissemination and Implementation Science in Cardiovascular Outcomes (DISCO) The goal of this K12 is to accelerate clinical applications of laboratory findings relevant to improve diagnosis and management into practice. AS a DISCO K12 Scholar, Dr. Pagidipati's primary role will be to develop independence in the area of late-state translation (T4) research. She will conduct health services and/or dissemination and implementation research focused on heart, lung, blood, and sleep disorders, and engage in career development activities.	75%	\$100,000	07/01/19-06/30/22
Investigator-initiated Grant (Pencina) Regeneron Inc. Secondary Prevention Risk Modelling The goal of this project is to develop a cardiovascular disease risk prediction model for individuals on statin therapy, both with and without prior cardiovascular disease, using the NIH pooled cohorts. Role: Co-investigator			10/16-
Google Baseline Study (Shah)			1/18-



The goal of this long-term study is to develop a well-defined reference, or "baseline," of good health as well as a rich data platform that may be used to better understand the transition from health to cardiovascular disease and identify additional risk factors for cardiovascular disease.

Role: Co-investigator

### **Duke Internal Award**

Translating Duke Health 1%-20% 06/01/19-05/31/21  
(Pagidipati)

Personalizing Cardiovascular Health: A population approach to promoting CVD resistance and resilience among individuals with obesity

This 3-year multi-million dollar study will explore heterogeneity in patients with obesity. Specifically, it will examine why certain individuals with obesity develop CVD while others do not, and why certain individuals with obesity lose weight with behavioral interventions while others do not. This project will also develop a translational health platform including the developing of an EHR-based cohort builder, process for remote biospecimen collection, and platform for longitudinal patient engagement in the research process.

Duke Bass Connection Global 1%-20% 2020  
Health Grant  
(Pagidipati-Co-PI)

### **COMPLETED**

T32 (Mark) (PI) 7/15-6/17

Completed 2 years of research in cardiovascular disease prevention, with a focus on hyperlipidemia and metabolic disorders, under the mentorship of Eric Peterson, MD at the Duke Clinical Research Institute.

Executive Director's Fund 12/15-6/17  
(Pagidipati) (PI)

Obesity Prevalence and Management in the Duke Health System

The goal of this project was to examine the prevalence and management patterns of obesity in the Duke Primary Care population.

Role: PI

Exenatide Study of 7/15-7/17  
Cardiovascular Event Lowering  
(EXSCEL) Trial (Hernandez)  
(PI)

Contributed as study clinician for this large randomized control trial studying the cardiovascular safety of exenatide, a once-weekly GLP-1 agonist used in type II diabetes mellitus.

Supported by Astra Zeneca, Inc.

Role: Co-investigator

Investigator-initiated Grant, 1/16-7/18  
Novartis Inc. (Pencina) (PI)

Hs-CRP elevation post-myocardial infarction

The goal of this project is to determine the prevalence of elevated high sensitivity C-reactive protein (hs-CRP) levels in individuals with a prior myocardial infarction, and to determine the degree to which standard cardiovascular risk factors can account for the variability in hs-CRP levels in this population.

Role: Co-investigator

Investigator-initiated Grant, 6/16-7/18  
Alexion Inc. (Reed) (PI)

Hyperlipidemia in the young

The goal of this project is to examine the cardiovascular risk of young adults with severe hyperlipidemia, using the NIH pooled cohorts.  
Role: Co-investigator

Investigator-initiated Grant, 1/17-  
Sanofi Inc. (Goldstein) (PI)  
Diabetes hospitalization risk modelling

The goal of this project is to develop a model to predict 1-year all-cause and cause-specific hospitalization in individuals with diabetes presenting for an outpatient appointment within the Duke Health System, using electronic health record data and machine learning techniques.  
Role: Co-investigator

DCRI Innovation Grant 2/17-2/18  
(Pagidipati) (PI)  
Prediabetes risk modelling

The goal of this project is to develop a cardiovascular disease risk prediction model for individuals with prediabetes using the NIH pooled cohorts.  
Role: PI

DCRI 7030 (Goldstein) 2%-5.9% \$176,593 12/30/16-12/03/19  
Sanofi-Aventis, Deutschland GmbH  
DM Admission Risk

The goals of the study include: Aim 1 will fully describe the diabetic patients. This will provide insight into the types of patients serviced by DUMC and can be used to assess which patients may be eligible for clinical trials. Aims 2 and 3 will establish insight into risk for hospitalization so that people who need proactive and/or more aggressive treatment such as escalated therapy can be identified. Dr. Pagidipati will provide clinical and cardiology expertise in support of the statistical analysis and publication of the research findings.

AMAR-02 (Navar) 1%-5% \$414,044 05/01/18-10/31/19  
Amarin Corporation  
Hypertriglyceridemia Observational Studies

To evaluate the cumulative risk of prolonged exposure to hypertriglyceridemia in the NIH pooled cohorts

DCRI 7775 (Pagidipati) 2%-9% \$358,374 04/01/19-10/31/19  
Medimmune, Inc.  
MEDI-0382: T2D, NASH, Obesity

Letter of intent (LOI) to Support Design & Start-Up for MedImmune Program of Phase I and/or II-b and/or Phase III Studies within the Following Indications: Type 2 Diabetes, NASH, and Obesity for Adults and Children

**PENDING: NONE**

**OTHER: NONE**

**OVERLAP: NONE**